A 50% stake in PanTera NV, a Joint-Venture 
with 
SCK-CEN 
(StudieCentrum 
voor 
Kernenergie - Centre dEtude de lenergie 
Nucleaire), the Belgian nuclear research 
centre based in Mol, with a contribution to the 
share capital of EUR 20.4 million. The JV will 
be active in the nuclear medicine, more 
specifically it will develop, produce and 
distribute the isotope Ac.225. A receivable of EUR 1.5 million on NHa SA 
and EUR 1 million on PanTera NV.